Skip to content
★ Sign in to follow
BF
Total declarations
94
Companies
2
▲ Purchases (79 ops.)
€490k
▼ Sales (0 ops.)
—

Latest filing published 26 Sept 2017 for Anixa Biosciences Inc.

Insider track record

Disclosed buys
79
Disclosed sells
0
Signal history

Closed purchases

Market purchases
79
Positive at T+90
47%
Median T+90
-6.1%

Based on 79 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 05 Jul 2016 · 3778 days ago · €13k
    -70.0%
    Entry US$3.20 · Close at T+365 US$0.96
  • Filed 29 Jun 2016 · 3784 days ago · €1,148
    -63.4%
    Entry US$3.14 · Close at T+365 US$1.15
  • Filed 20 Jun 2016 · 3793 days ago · €658
    -74.2%
    Entry US$3.33 · Close at T+365 US$0.86
  • Filed 13 Jun 2016 · 3800 days ago · €2,633
    -71.8%
    Entry US$3.30 · Close at T+365 US$0.93
  • Filed 10 Jun 2016 · 3803 days ago · €1,578
    -73.4%
    Entry US$3.31 · Close at T+365 US$0.88

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Bruce F. Johnson: trading record in brief

Filings by Bruce F. Johnson span 2 companies, the busiest being Anixa Biosciences Inc and CME Group Inc. We count 94 filings; the first trade dates from 25 May 2006 and the latest from 22 September 2017.

No open-market sale appears; the market trades are 79 purchases worth €490k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 12 share grants and 1 option exercise.

A typical purchase (the median) is worth €2,986. Of 21 purchases, 7 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. After 79 purchases with a full 90-day history, the hit rate stands at 47% and the median 90-day move at -6.1%. These figures describe past trades and do not predict future prices.

On 26 September 2017 came the latest disclosure, a share grant in Anixa Biosciences Inc. The most recent open-market purchase was published on 5 July 2016, 3,778 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Companies and markets linked to Bruce F. Johnson

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations93 total
  • ◆
    DirectorExecutivesAnixa Biosciences Inc
    0SEC
    50,000 sharesCommon StockSEC:0001513162-17-000264:0
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    14,670 USD20SEC
    4,500 shares@ US$3.2630.8% of flowCommon StockSEC:0001513162-16-000900:0
    Canonical exit: 28 Sept 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    1,264 USD17SEC
    400 shares@ US$3.162.7% of flowCommon StockSEC:0001513162-16-000899:0
    Canonical exit: 25 Sept 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    740 USD17SEC
    200 shares@ US$3.701.5% of flowCommon StockSEC:0001513162-16-000894:0
    Canonical exit: 14 Sept 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    668 USD17SEC
    200 shares@ US$3.341.4% of flowCommon StockSEC:0001513162-16-000894:1
    Canonical exit: 15 Sept 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    2,979 USD18SEC
    900 shares@ US$3.316.1% of flowCommon StockSEC:0001513162-16-000885:0
    Canonical exit: 7 Sept 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    1,800 USD17SEC
    500 shares@ US$3.603.7% of flowCommon StockSEC:0001513162-16-000884:0
    Canonical exit: 6 Sept 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    5,085 USD18SEC
    1,500 shares@ US$3.3910.6% of flowCommon StockSEC:0001513162-16-000882:0
    Canonical exit: 31 Aug 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    1,625 USD17SEC
    500 shares@ US$3.253.4% of flowCommon StockSEC:0001513162-16-000882:1
    Canonical exit: 1 Sept 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    317 USD17SEC
    100 shares@ US$3.170.7% of flowCommon StockSEC:0001513162-16-000880:0
    Canonical exit: 25 Aug 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    8,313 USD19SEC
    2,504 shares@ US$3.3217.4% of flowCommon StockSEC:0001513162-16-000880:1
    Canonical exit: 29 Aug 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    262 USD17SEC
    100 shares@ US$2.620.5% of flowCommon StockSEC:0001513162-16-000812:0
    Canonical exit: 18 Jul 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    584 USD17SEC
    200 shares@ US$2.921.2% of flowCommon StockSEC:0001513162-16-000812:1
    Canonical exit: 18 Jul 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    592 USD17SEC
    200 shares@ US$2.961.2% of flowCommon StockSEC:0001513162-16-000812:2
    Canonical exit: 19 Jul 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    564 USD17SEC
    200 shares@ US$2.821.2% of flowCommon StockSEC:0001513162-16-000802:0
    Canonical exit: 6 Jul 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    1,505 USD32SEC
    500 shares@ US$3.013.1% of flowCommon StockSEC:0001513162-16-000787:0
    Canonical exit: 29 Jun 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    302 USD32SEC
    100 shares@ US$3.020.6% of flowCommon StockSEC:0001513162-16-000787:1
    Canonical exit: 29 Jun 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    303 USD32SEC
    100 shares@ US$3.030.6% of flowCommon StockSEC:0001513162-16-000782:0
    Canonical exit: 26 Jun 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    1,987 USD32SEC
    720 shares@ US$2.764.1% of flowCommon StockSEC:0001513162-16-000768:0
    Canonical exit: 21 Jun 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    1,425 USD30SEC
    500 shares@ US$2.852.9% of flowCommon StockSEC:0001513162-16-000765:0
    Canonical exit: 16 Jun 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    1,480 USD28SEC
    500 shares@ US$2.963.1% of flowCommon StockSEC:0001513162-16-000754:0
    Canonical exit: 12 Jun 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    1,470 USD26SEC
    500 shares@ US$2.943.1% of flowCommon StockSEC:0001513162-16-000746:0
    Canonical exit: 7 Jun 2016 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    6,286 USD0SEC
    1,400 shares@ US$4.49Common StockSEC:0001513162-15-000565:0
    Canonical exit: 24 Dec 2015 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    515 USD0SEC
    100 shares@ US$5.15Common StockSEC:0001513162-15-000561:0
    Canonical exit: 20 Dec 2015 (T+90)
  • ▲
    DirectorExecutivesAnixa Biosciences Inc
    3,372 USD0SEC
    600 shares@ US$5.62Common StockSEC:0001513162-15-000555:0
    Canonical exit: 15 Dec 2015 (T+90)

25 of 93 declarations